Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Parkinson disease

Can a new trial end controversy over when to use levodopa?

Levodopa is the standard therapy for Parkinson disease, but prolonged use promotes the development of adverse motor effects. A new trial compared the effectiveness of levodopa administration early in the disease with therapies that used alternative dopaminergic agents before levodopa. No clinically relevant differences were found between the treatment strategies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Rascol, O. et al. Limitations of current Parkinson's disease therapy. Ann Neurol. 53 (Suppl. 3), S3–S12 (2003).

    Article  CAS  Google Scholar 

  2. Rascol, A., Guiraud, B., Montastruc, J. L., David, J. & Clanet, M. Long-term treatment of Parkinson's disease with bromocriptine. J. Neurol. Neurosurg. Psychiatry 42, 143–150 (1979).

    Article  CAS  Google Scholar 

  3. [No authors listed] Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 321, 1364–1371 (1989).

  4. PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet

  5. Lang, A. E. & Lozano, A. M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044–1053 (1998).

    Article  CAS  Google Scholar 

  6. Olanow, W. C. et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov. Disord. 28, 1064–1071 (2013).

    Article  CAS  Google Scholar 

  7. Weintraub, D. et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67, 589–595 (2010).

    Article  Google Scholar 

  8. Ory-Magne, F. et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82, 300–307 (2014).

    Article  CAS  Google Scholar 

  9. US National Library of Medicine. [online], (2013).

  10. Pahwa, R. et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat. Disord. 20, 142–148 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Olivier Rascol.

Ethics declarations

Competing interests

The author has served as a scientific advisor for and received honoraria from AbbVie, Britannia, Boerhinger Ihghelheim, GlaxoSmithKline, Impax, Lundbeck, Novartis, Servier, Teva, UCB and Xenoport.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rascol, O. Can a new trial end controversy over when to use levodopa?. Nat Rev Neurol 10, 488–489 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing